Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-166747
Filing Date
2026-04-21
Accepted
2026-04-21 16:05:36
Documents
14
Period of Report
2026-04-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A evmn-20260421.htm   iXBRL DEF 14A 954141
2 GRAPHIC img41218707_0.gif GRAPHIC 4027
3 GRAPHIC img41218707_1.jpg GRAPHIC 472105
4 GRAPHIC img41218707_2.jpg GRAPHIC 203792
  Complete submission text file 0001193125-26-166747.txt   2736630

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evmn-20260421.xsd EX-101.SCH 7527
17 EXTRACTED XBRL INSTANCE DOCUMENT evmn-20260421_htm.xml XML 6625
Mailing Address 1891 PAGE MILL RD PALO ALTO CA
Business Address 1891 PAGE MILL RD PALO ALTO CA (650) 223-7745
Evommune, Inc. (Filer) CIK: 0002044725 (see all company filings)

EIN.: 850742575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-42938 | Film No.: 26879421
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)